Umer Raffat – Evercore ISI Institutional Equities, Research Division – Senior MD & Senior
Analyst of Equity Research
But we shouldnt expect so theres been conversations. This question is not on the pro forma
guidance, but theres been a lot of questions on whether pro forma numbers are really $19 billion to $20 billion or is it closer to $18 billion top line. And there was a lot of comments where Mylan has sort of hinted at a lot of
things on the earnings call. But my question is, should we expect a meaningful update on that at JP Morgan? Or should we really wait for the earnings call?
Kenneth S. Parks – Mylan N.V. – CFO
I think weve got a way I think we as you can imagine, while the deal was announced July 29, there is a lot of
activity going on right now, including looking at the markets, bringing the commercial teams together to assess markets. I think we need to learn more to tell you how definitively well tell you something at JP Morgan versus end of February
versus closer to the deal closing. So well learn more to be able to give you more as soon as we reasonably can.
Umer Raffat – Evercore ISI Institutional
Equities, Research Division – Senior MD & Senior Analyst of Equity Research
Sounds
great. So next time is all China when we meet. Thank you, guys for being here.
Forward-Looking Statements
This transcript contains forward-looking statements. Such forward-looking statements may include, without limitation, statements about the proposed
combination of Upjohn Inc. (Newco) and Mylan N.V. (Mylan), which will immediately follow the proposed separation of the Upjohn business (the Upjohn Business) from Pfizer Inc. (Pfizer) (the
proposed transaction), the expected timetable for completing the proposed transaction, the benefits and synergies of the proposed transaction, future opportunities for the combined company and products and any other statements regarding
Pfizers, Mylans, the Upjohn Businesss or the combined companys future operations, financial or operating results, capital allocation, dividend policy, debt ratio, anticipated business levels, future earnings, planned
activities, anticipated growth, market opportunities, strategies, competitions, and other expectations and targets for future periods. Forward-looking statements may often be identified by the use of words such as will, may,
could, should, would, project, believe, anticipate, expect, plan, estimate, forecast, potential,
pipeline, intend, continue, target, seek and variations of these words or comparable words. Because forward-looking statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the parties ability to meet expectations regarding
the timing, completion and accounting and tax treatments of the proposed transaction; changes in relevant tax and other laws; the parties ability to consummate the proposed transaction; the conditions to the completion of the proposed
transaction, including receipt of approval of Mylans shareholders, not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or
on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with accounting principles
generally accepted in the United States of America and related standards or on an adjusted basis; the integration of Mylan and Newco being more difficult, time consuming or costly than expected; Mylans, the Upjohn Businesss and the
combined companys failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in
connection with the proposed transaction within the expected time frames or at all or to successfully integrate Mylan and Newco; customer loss and business disruption being greater than expected following the proposed transaction; the retention of
key employees being more difficult following the proposed transaction; any regulatory, legal or other impediments to Mylans, the Upjohn Businesss or the combined companys ability to bring new products to market, including but not
limited to where Mylan, the Upjohn Business or the combined company uses its business judgment and decides to
